Summary
The response makes multiple claims about isosorbide mononitrate and generic availability/differences that are not supported by the provided FDA label excerpts, which instead concern isosorbide dinitrate immediate-release tablets and include specific indications, dosing intervals, contraindications, interactions, and safety information.
Category Scores
Accurate Statements
Unsupported Statements
Isosorbide mononitrate is widely available as a generic medicine in many markets.
No information in the provided FDA-approved labeling excerpts addresses generic availability or market status.
Key patent protections for the active ingredient of isosorbide mononitrate are long expired.
No information in the provided FDA-approved labeling excerpts addresses patents or exclusivity.
Generic versions of isosorbide mononitrate are sold under the chemical name "isosorbide mononitrate" by multiple manufacturers.
The provided label excerpts do not discuss mononitrate naming conventions or manufacturers.
Generic isosorbide mononitrate products should match the branded drug in key ways.
The provided label excerpts do not address generic equivalence expectations.
The exact look and dosing options of generic isosorbide mononitrate can differ by manufacturer.
The provided label excerpts do not discuss differences among generic manufacturers or product appearance/strength options.
Common tablet strengths of generic isosorbide mononitrate vary by product line.
The provided label excerpts do not provide any tablet strength information for isosorbide mononitrate or discuss variability by product line.
Generic isosorbide mononitrate products can differ in dosage form, including immediate-release versus extended-release.
The provided label excerpts do not address dosage form differences for isosorbide mononitrate generics.
The dosing frequency for isosorbide mononitrate is driven by the formulation and the prescription.
The provided label excerpts provide specific dosing interval guidance only for isosorbide dinitrate immediate-release tablets and do not support this general statement about mononitrate dosing frequency drivers.
In many countries, "isosorbide mononitrate" is the generic name, while brands differ.
The provided label excerpts do not discuss international generic-name conventions.
Switching between generic versions of nitrate medicines like isosorbide mononitrate usually shouldn’t be a problem when the same strength and the same release type (extended-release vs immediate-release) are kept.
The provided label excerpts do not address switching between generic versions or interchangeability guidance.
The main practical risks with changing brands of isosorbide mononitrate are taking the wrong formulation or the wrong dosing frequency.
The provided label excerpts do not identify risks of switching brands of mononitrate products, nor do they support this as the main practical risk.
Contradictions
Low
AI Statement
Isosorbide mononitrate ... (multiple statements throughout the response)
Label Reference
Provided FDA label excerpts are for Isosorbide Dinitrate Tablets USP (ISDN), immediate-release oral tablets; no FDA label excerpts are provided for isosorbide mononitrate.
Important Omissions
FDA-label-specific dosing safety requirements for the labeled product (isosorbide dinitrate immediate-release tablets), including the required daily dose-free interval (at least 14 hours) to minimize tolerance and the stated usual starting and maintenance dosing ranges/frequency (two or three times daily), as applicable.
Importance:
High
FDA-label contraindication information for the labeled product (e.g., contraindication in patients allergic to ISDN or ingredients).
Importance:
Moderate
FDA-label warnings/precautions relevant to safety, including sildenafil interaction leading to severe hypotension and cautions about hypotension/syncope/bradycardia and tolerance/dose-free interval.
Importance:
High
FDA-label drug interaction information (e.g., additive vasodilatory effects; sildenafil amplification; alcohol additive effects).
Importance:
Moderate
FDA-label adverse reaction information (e.g., headache, lightheadedness, hypotension, syncope/crescendo angina/rebound hypertension).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response focuses on generic/patent/market interchangeability for isosorbide mononitrate without matching the provided FDA labeling content, which pertains to isosorbide dinitrate immediate-release tablets and includes specific safety-critical guidance (e.g., dose-free interval to reduce tolerance and serious sildenafil interaction warnings).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims are about isosorbide mononitrate and generic/patent/interchangeability topics that are not supported by the provided FDA label excerpts (which are for isosorbide dinitrate immediate-release tablets).
Suggested Improvement
Limit claims to information explicitly supported by the provided FDA label excerpts for isosorbide dinitrate immediate-release tablets (indication, dosing regimen with at least 14-hour dose-free interval, contraindications, warnings/precautions including sildenafil interaction, drug interactions, and adverse reactions). Avoid generic/market/patent interchangeability statements unless the supplied labeling includes them.